<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.targetedonc.com/view/desjardins-recent-developments-reshaping-brain-cancer-care</loc>
      <lastmod>2026-11-20T19:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Dr Desjardins on Recent Developments Reshaping Brain Cancer Care]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/daraxonrasib-gnp-first-line-metastatic-pancreatic-cancer</loc>
      <lastmod>2026-11-20T17:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T17:00:00Z</news:publication_date>
        <news:title><![CDATA[Daraxonrasib Plus Chemo Yields Durable Response in First-Line PDAC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/second-cancer-risk-declines-in-modern-era-hodgkin-lymphoma-survivors</loc>
      <lastmod>2026-11-20T16:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Second Cancer Risk Declines in Modern-Era Hodgkin Lymphoma Survivors]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/can-intismeran-autogene-plus-pembrolizumab-improve-melanoma-outcomes</loc>
      <lastmod>2026-11-20T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Can Intismeran Autogene Plus Pembrolizumab Improve Melanoma Outcomes?]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/hypofractionated-radiotherapy-postmastectomy-imni-breast-cancer</loc>
      <lastmod>2026-11-20T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Hypofractionated RT Noninferior After Mastectomy in Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/managing-rash-stomatitis-and-other-toxicities-in-hr-her2-negative-advanced-breast-cancer</loc>
      <lastmod>2026-11-20T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Managing Rash, Stomatitis, and Other Toxicities in HR+/HER2-Negative Advanced Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/initiating-capivasertib-and-managing-early-toxicities-in-hr-her2-negative-advanced-breast-cancer</loc>
      <lastmod>2026-11-20T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Initiating Capivasertib and Managing Early Toxicities in HR+/HER2-Negative Advanced Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/pet-guided-strategy-may-spare-chemotherapy-in-her2-positive-breast-cancer</loc>
      <lastmod>2026-11-20T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T13:00:00Z</news:publication_date>
        <news:title><![CDATA[PET-Guided Strategy May Spare Chemotherapy in HER2-Positive Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/patient-factors-guiding-treatment-choice-in-tp53-mutated-nsclc</loc>
      <lastmod>2026-11-20T12:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Patient Factors Guiding Treatment Choice in TP53-Mutated NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/tp53-co-mutation-and-second-clinical-scenario-presentation</loc>
      <lastmod>2026-11-20T12:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T12:00:00Z</news:publication_date>
        <news:title><![CDATA[TP53 Co-Mutation and Second Clinical Scenario Presentation]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/sequencing-toxicity-top-concerns-her2-mutant-nsclc</loc>
      <lastmod>2026-11-19T22:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T22:00:00Z</news:publication_date>
        <news:title><![CDATA[Treatment Sequencing and Toxicity Are Top Concerns in HER2-Mutant NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/can-ai-fix-clinical-trial-access-in-oncology</loc>
      <lastmod>2026-11-19T21:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T21:00:00Z</news:publication_date>
        <news:title><![CDATA[Can AI Fix Clinical Trial Access in Oncology? ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/can-amivantamab-change-the-hnscc-landscape-</loc>
      <lastmod>2026-11-19T19:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Can Amivantamab Change the HNSCC Landscape?]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/fda-grants-rmat-designation-iscib1-advanced-melanoma</loc>
      <lastmod>2026-11-19T17:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T17:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Grants RMAT Designation to iSCIB1+ in Advanced Melanoma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/sonesitatug-vedotin-priority-review-cldn18-2-gastric-cancer</loc>
      <lastmod>2026-11-20T19:24:00.000Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T16:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastric Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/does-pimicotinib-expand-options-in-tenosynovial-giant-cell-tumor-</loc>
      <lastmod>2026-11-19T15:30:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T15:30:00Z</news:publication_date>
        <news:title><![CDATA[Does Pimicotinib Expand Options in Tenosynovial Giant Cell Tumor?]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/fda-removes-pcnsl-limitation-from-liso-cel-label</loc>
      <lastmod>2026-11-20T19:26:00.000Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Removes PCNSL Limitation From Liso-Cel Label]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/oncologists-weigh-age-and-drug-interactions-in-mhspc-treatment-selection</loc>
      <lastmod>2026-11-18T22:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T22:00:00Z</news:publication_date>
        <news:title><![CDATA[Oncologists Weigh Age and Drug Interactions in mHSPC Treatment Selection]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/alternating-pazopanib-and-bevacizumab-shows-promise-in-metastatic-ccrcc</loc>
      <lastmod>2026-11-18T21:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T21:00:00Z</news:publication_date>
        <news:title><![CDATA[Alternating Pazopanib and Bevacizumab Shows Promise in Metastatic ccRCC]]></news:title>
      </news:news>
	</url></urlset>